- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Regulatory effect of liraglutide on hypoglycemia in patients with type 1 diabetes mellitus： a meta-analysis
- ZHONGGUO YAOFANG Vol. 35, Issue 23, Pages: 2908-2914(2024)
- 作者机构：
山东第二医科大学基础医学院/山东省高等院校重点实验室，山东 潍坊 261053
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.23.12
CLC： R977.1+5Published：15 December 2024，
Received：22 April 2024，
Revised：07 September 2024，
- 稿件说明：
移动端阅览
王岩,靳方馨,李敏讷等.利拉鲁肽对1型糖尿病患者低血糖调节作用的Meta分析 Δ[J].中国药房,2024,35(23):2908-2914.
WANG Yan,JIN Fangxin,LI Minne,et al.Regulatory effect of liraglutide on hypoglycemia in patients with type 1 diabetes mellitus： a meta-analysis[J].ZHONGGUO YAOFANG,2024,35(23):2908-2914.
王岩,靳方馨,李敏讷等.利拉鲁肽对1型糖尿病患者低血糖调节作用的Meta分析 Δ[J].中国药房,2024,35(23):2908-2914. DOI： 10.6039/j.issn.1001-0408.2024.23.12.
WANG Yan,JIN Fangxin,LI Minne,et al.Regulatory effect of liraglutide on hypoglycemia in patients with type 1 diabetes mellitus： a meta-analysis[J].ZHONGGUO YAOFANG,2024,35(23):2908-2914. DOI： 10.6039/j.issn.1001-0408.2024.23.12.
摘要
目的
2
系统评价利拉鲁肽对1型糖尿病患者低血糖的调节作用，为临床治疗1型糖尿病时防控低血糖提供循证证据。
方法
2
计算机检索The Cochrane Library、PubMed、Embase、Web of Science和中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、万方数据库和维普数据库（VIP），检索时限均为建库至2023年6月30日。检索并按纳排标准筛选利拉鲁肽作用于1型糖尿病患者低血糖的临床随机对照试验，并对纳入的研究进行数据提取、分组及亚组Meta分析。
结果
2
最终纳入11篇随机对照试验，共1 685例患者。Meta分析结果显示，1.2 mg利拉鲁肽治疗1型糖尿病时可降低患者低血糖发生频率[OR＝0.81，95%CI（0.74，0.88），
P
＜0.01
]
，但1.8 mg利拉鲁肽治疗时则可提高患者低血糖发生频率[OR＝1.33，95%CI（1.23，1.44），
P
＜0.01
]
。利拉鲁肽对1型糖尿病患者低血糖的作用与低血糖持续时间无关[MD＝－0.29，95%CI （－1.21，0.63），
P
＝0.53
]
，且不增加1型糖尿病患者严重低血糖发生率[OR＝0.87，95%CI（0.57，1.33），
P
＝0.53
]
。利拉鲁肽可降低1型糖尿病患者的糖化血红蛋白水平[MD＝ －1.39，95%CI（－2.65，－0.13），
P
＝0.03
]
、体重[MD＝－4.28，95%CI（－5.01，－3.55），
P
＜0.01
]
和体重指数[MD＝－1.20，95%CI （－1.80，－0.60），
P
＜0.01
]
。
结论
2
利拉鲁肽对1型糖尿病患者低血糖具有双向调节作用，其作用与利拉鲁肽的剂量相关，即适量利拉鲁肽（1.2 mg）可抑制T1DM患者低血糖的发生，增量利拉鲁肽（1.8 mg）则可促进1型糖尿病患者低血糖的发生。
Abstract
OBJECTIVE
2
To systematically evaluate the regulatory effect of liraglutide on hypoglycemia in patients with type 1 diabetes mellitus （T1DM） and provide evidence for the prevention and control of hypoglycemia in the clinical treatment of T1DM.
METHODS
2
Electronic databases including The Cochrane Library， PubMed， Embase， Web of Science， China Biology Medicine Disc （CBM）， CNKI， Wanfang database， and VIP database were searched from the inception of the databases to June 30， 2023. The clinical randomized controlled trials （RCTs） of liraglutide on hypoglycemia in T1DM patients were screened according to inclusion and exclusion criteria. Data extraction， grouping， and subgroup meta-analysis were conducted for the included studies.
RESULTS
2
A total of 11 RCTs involving 1 685 patients were ultimately included. Meta-analysis results showed that treatment with 1.2 mg liraglutide could reduce the frequency of hypoglycemia in patients with T1DM [OR＝0.81， 95%CI （0.74， 0.88），
P
＜0.01
]
， while treatment with 1.8 mg liraglutide could increase the frequency of hypoglycemia [OR＝1.33， 95%CI （1.23， 1.44），
P
＜0.01
]
. The effect of liraglutide on hypoglycemia in patients with T1DM was not correlated with the duration of hypoglycemia [MD＝ －0.29， 95%CI （－1.21， 0.63），
P
＝0.53
]
， and did not increase the incidence of severe hypoglycemia in these patients [OR＝0.87， 95%CI （0.57， 1.33），
P
＝0.53
]
. Liraglutide could reduce the levels of glycated hemoglobin [MD＝－1.39， 95%CI （－2.65， －0.13），
P
＝0.03
]
， weight [MD＝－4.28， 95%CI （－5.01， －3.55），
P
＜0.01
]
， and body mass index [MD＝－1.20， 95%CI （－1.80， －0.60），
P
＜0.01
]
in them.
CONCLUSIONS
2
Liraglutide has a bidirectional regulatory effect on hypoglycemia in patients with T1DM， which is correlated with the dose of liraglutide. An appropriate dose of liraglutide （1.2 mg） can inhibit hypoglycemia in these patients， while an increased dose of liraglutide （1.8 mg） can promote hypoglycemia in them.
关键词
利拉鲁肽1型糖尿病低血糖双向调节
Keywords
type 1 diabetes mellitushypoglycemiabidirectional regulation
references
QUATTRIN T，MASTRANDREA L D，WALKER L S K. Type 1 diabetes[J]. Lancet，2023，401（10394）：2149-2162.
FRIER B M. Hypoglycaemia in diabetes mellitus：epidemiology and clinical implications[J]. Nat Rev Endocrinol，2014，10（12）：711-722.
NAKHLEH A，SHEHADEH N. Hypoglycemia in diabetes：an update on pathophysiology，treatment，and prevention[J]. World J Diabetes，2021，12（12）：2036-2049.
SEAQUIST E R，ANDERSON J，CHILDS B，et al. Hypoglycemia and diabetes：a report of a workgroup of the American Diabetes Association and the Endocrine Society[J]. Diabetes Care，2013，36（5）：1384-1395.
ZHANG Y Q，PARAJULI K R，FAVA G E，et al. GLP-1 receptor in pancreatic α-cells regulates glucagon secretion in a glucose-dependent bidirectional manner[J]. Diabetes，2019，68（1）：34-44.
ANDERSEN A，KNOP F K，VILSBØLL T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes[J]. Drugs，2021，81（9）：1003-1030.
WANG W，GAO Y，CHEN D W，et al. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus：a systematic review and meta-analysis[J]. Diabetes Res Clin Pract，2017，129：213-223.
DIMITRIOS P，MICHAEL D，VASILIOS K，et al. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes：a systematic review and meta-analysis[J]. Curr Diabetes Rev，2020，16（4）：313-326.
DIJKGRAAF M G W，HAUKOOS J，ITANI K M F. Practical guide to design choice of randomized clinical trials in surgery[J]. JAMA Surg，2022，157（12）：1154-1155.
MUNEER M. Hypoglycaemia[J]. Adv Exp Med Biol，2021，1307：43-69.
LUO D H，WAN X，LIU J M，et al. Optimally estimating the sample mean from the sample size，median，mid-range，and/or mid-quartile range[J]. Stat Methods Med Res，2018，27（6）：1785-1805.
WAN X，WANG W Q，LIU J M，et al. Estimating the sample mean and standard deviation from the sample size，median，range and/or interquartile range[J]. BMC Med Res Methodol，2014，14：135.
HIGGINS J P，ALTMAN D G，GøTZSCHE P C，et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials [J]. BMJ，2011，343：d5928.
AHRÉN B，HIRSCH I B，PIEBER T R，et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes：the ADJUNCT TWO randomized trial[J]. Diabetes Care，2016，39（10）：1693-1701.
BALLAV C，DHERE A，KENNEDY I，et al. Lixisenatide in type 1 diabetes：a randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients[J]. Endocrinol Diabetes Metab，2020，3（3）：e00130.
DEJGAARD T F，FRANDSEN C S，HANSEN T S，et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control （Lira-1）：a randomised，double-blind，placebo-controlled trial[J]. Lancet Diabetes Endocrinol，2016，4（3）：221-232.
DEJGAARD T F，SCHMIDT S，FRANDSEN C S，et al. Liraglutide reduces hyperglycaemia and body weight in overweight，dysregulated insulin-pump-treated patients with type 1 diabetes：the Lira Pump trial：a randomized，double-blinded，placebo-controlled trial[J]. Diabetes Obes Metab，2020，22（4）：492-500.
DUBÉ M C，D’AMOURS M，WEISNAGEL S J. Beyond glycaemic control：a cross-over，double-blinded，24-week intervention with liraglutide in type 1 diabetes[J]. Diabetes Obes Metab，2018，20（1）：178-184.
FRANDSEN C S，DEJGAARD T F，HOLST J J，et al. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes：a randomized，placebo-controlled，double-blind parallel study[J]. Diabetes Care，2015，38（12）：2250-2257.
JOHANSEN N J，DEJGAARD T F，LUND A，et al. Efficacy and safety of meal-time administration of short- acting exenatide for glycaemic control in type 1 diabetes （MAG1C）：a randomised，double-blind，placebo-controlled trial[J]. Lancet Diabetes Endocrinol，2020，8（4）：313-324.
KUHADIYA N D，DHINDSA S，GHANIM H，et al. Addition of liraglutide to insulin in patients with type 1 diabetes：a randomized placebo-controlled clinical trial of 12 weeks[J]. Diabetes Care，2016，39（6）：1027-1035.
MATHIEU C，ZINMAN B，HEMMINGSSON J U，et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes：the ADJUNCT ONE treat-to-target randomized trial[J]. Diabetes Care，2016，39（10）：1702-1710.
PIEBER T R，DELLER S，KORSATKO S，et al. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin：a randomized，placebo-controlled，double-blind，crossover trial[J]. Diabetes Obes Metab，2015，17（8）：742-750.
VON HERRATH M，BAIN S C，BODE B，et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes：a randomised，double-blind，placebo-controlled，phase 2 trial[J]. Lancet Diabetes Endocrinol，2021，9（4）：212-224.
LIU L L，SHAO Z，XIA Y，et al. Incretin-based therapies for patients with type 1 diabetes：a meta-analysis[J]. Endocr Connect，2019，8（3）：277-288.
FRANDSEN C S，DEJGAARD T F，ANDERSEN H U， et al. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or ga- stric emptying rate during hypoglycaemia：a randomized，placebo-controlled，double-blind，parallel-group study[J]. Diabetes Obes Metab，2017，19（6）：773-782.
GILON P. The role of α-cells in islet function and glucose homeostasis in health and type 2 diabetes[J]. J Mol Biol，2020，432（5）：1367-1394.
HUISING M O，VAN DER MEULEN T，HUANG J L， et al. The difference δ-cells make in glucose control[J]. Physiology，2018，33（6）：403-411.
RORSMAN P，HUISING M O. The somatostatin-secreting pancreatic δ-cell in health and disease[J]. Nat Rev Endocrinol，2018，14（7）：404-414.
ORCI L，BAETENS D，RUFENER C，et al. Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes[J]. Proc Natl Acad Sci U S A，1976，73（4）：1338-1342.
GÓMEZ DUMM C L，CÓNSOLE G M，LUNA G C， et al. Quantitative immunohistochemical changes in the endocrine pancreas of nonobese diabetic （NOD） mice[J]. Pancreas，1995，11（4）：396-401.
NOVIKOVA L，SMIRNOVA I V，RAWAL S，et al. Variations in rodent models of type 1 diabetes：islet morphology[J]. J Diabetes Res，2013，2013：965832.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.